At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 190 enrolled
Drug / intervention
Celecoxib +2 moredrug
Likely dose
Celecoxib 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Double-Blind, Phase 4 Study To Compare The Effect Of Celecoxib 100 Mg BID, Loxoprofen 60 Mg TID And Placebo On The Gastroduodenal Mucosa In Healthy Subjects
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Oct 14, 2009·Updated Feb 2, 2021
In Brief
A Phase 4 clinical trial evaluating Celecoxib, Loxoprofen, and 1 other intervention for Healthy Volunteers. Completed, enrolled 190 participants across 3 sites.
Detailed Summary
A study to confirm the superiority of celecoxib 100 mg BID to loxoprofen 60 mg TID in the incidence of gastroduodenal endoscopic ulcers after 2 weeks treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartNov 2009
Primary CompletionApr 2010
TodayJul 2026
First PostedOct 14, 2009
Enrollment StartNov 1, 2009
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.7 years ago
Interventions
Celecoxibdrug
Celecoxib 100mg tablet twice a day with meal for 2 weeks
Loxoprofendrug
Loxoprofen 60mg tablet three times a day with meal for 2 weeks
Placebodrug
Placebo tablet three times a day with meal for 2 weeks